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Background: Clinical activity of ankylosing spondylitis (AS) predicts the natural course of the disease and the
response to treatment. Several molecules are involved in new bone formation resulting in structural damage in
patients with AS. However, the link between the clinical and molecular phenomena has not yet been fully
established. The aim of the study was to investigate the relation between markers of bone remodeling and
inflammation with clinical activity and structural damage in AS.
Methods: We assessed the serum levels of sclerostin, Dickkopf-1 protein, Wingless protein-3a, bone morphogenic
protein-7, matrix metalloproteinase-3, osteoprotegerin, bone alkaline phosphatase and inflammatory markers in 50
AS patients with high disease activity (BASDAI ≥ 4), 28 with low disease activity (BASDAI <4), and 23 healthy
controls. Cervical and lumbar spine x-rays were performed in 46 patients to measure structural damage (mSASSS).
Results: Sclerostin level was significantly greater in high disease activity patients than in controls. Wingless
protein-3a and Dikkopf-1 protein levels were significantly lower in high activity group compared to low activity
group and controls. Negative correlation was found between sclerostin and Dikkopf-1 protein in high activity
group (R = −0.28, P = 0.048). The median mSASSS values were not different between patient groups.
Conclusions: Higher disease activity in AS may not be per se associated with greater new bone formation.
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Ankylosing spondylitis (AS) is a rheumatic disease char-
acterized by chronic inflammation and new bone forma-
tion leading to bone remodeling, primarily in the axial
skeleton [1]. Bone remodeling in AS is a dynamic
process involving numerous molecules interconnected
within the multilevel positive and negative feedback net-
works [2]. The link between inflammation and bone re-
modeling has not been fully explained. Tumour Necrosis
Factor alpha (TNF), a pivotal pro-inflammatory cytokine* Correspondence: mariuszk@mp.pl
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reproduction in any medium, provided the orin AS is responsible for induction of Dickkopf-1 (Dkk-1)
and sclerostin [3], which in turn down-regulate bone
formation by inhibition of Wingless proteins (Wnt) and
bone morphogenic proteins (BMPs). The latter two are
the key inducers of osteoblastogenesis and new bone
formation [4,5].
Several other molecules are involved in bone remodel-
ing in spondyloarthritis. Wnt up-regulates expression of
osteoprotegerin (OPG), which is responsible for inhi-
bition of osteoclastogenesis and thus bone resorption [6]
by attenuating influence of receptor activator of nuclear
factor kappa B ligand (RANKL) on mature osteoclasts
and their precursors [7]. Matrix metaloproteinases-3
(MMP-3) is responsible for degradation of extracellular
matrix of bone during inflammation [8] and was foundl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical and laboratory characteristics of ankylosing
spondylitis patients, with high and low disease activity and
controls
High disease
activity
(BASDAI≥ 4)
Low disease
activity
(BASDAI < 4)
Healthy
controls
n = 50 n = 28 n = 23
age in years (SD) 37.8 (11.6)*& 32.0 (6.6) 32.3 (7.5)
disease duration in years
(SD)
9.0 (6.7) 7.2 (5.0) NA
BASDAI (SEM) 7.17 (0.24)* 2.79 (0.15) NA
ESR mm/hr (SEM) 34.7 (3.09)*& 21.3 (3.74)& 6.3 (0.79)
CRP mg/l (SEM) 23.4 (3.87)*& 10.7 (2.24) & 0.89 (0.16)
TNF alpha pg/ml (SEM) 2.03 (0.19) & 2.56 (0.74) & 1.77 (0.24)
IL-6 pg/ml (SEM) 6.01 (1.53) & 4.4 (0.66) & 0.80 (0.007)
IL-18 pg/ml (SEM) 446.25 (30.62) 418.0 (28.2) 394.0 (21.8)
Dkk-1 pg/ml (SEM) 818.7 (114.9)* & 1692.7 (122.3) & 1349.3 (82.7)
sclerostin ng/ml (SEM) 0.34 (0.09) & 0.21 (0.12) 0.12 (0.09)
Wnt-3a ng/ml (SEM) 12.6 (2.46)* & 26.3 (2.24) & 16.9 (2.4)
BMP-7 pg/ml (SEM) 5.46 (0.92) 5.67 (0.97) 5.6 (1.09)
MMP-3 ng/ml (SEM) 11.6 (2.46)* & 56.1 (36.7) 13.1 (1.28)
OPG pmol/ml (SEM) 4.8 (0.34) & 4.0 (0.21) 3.9 (1.16)
BALP U/l (SEM) 76.9 (9.15) 57.7 (3.36) 53.4 (8.0)
mSASSS 8 (4-51) 8 (1-22) NA
median (5–95 percentile)
*p < 0,05 vs. low disease activity group.
&p < 0,05 vs. control group.
AS Ankylosing spondylitis, BASDAI Bath ankylosing spondylitis disease activity
index; ESR erythrocyte sedimentation rate, CRP C-reactive protein, TNF alpha
Tumour necrosis factor alpha, IL-6 interleukin 6, IL-18 Interleukin 18, Dkk-1
Dickkopf-1 protein, Wnt-3a wingless protein-3a, BMP-7 Bone morphogenic
protein-7, MMP-3 Matrix metalloproteinase 3, OPG Osteoprotegerin, BALP Bone
alkaline phosphatase, mSASSS Modified Stoke’s ankylosing spondylitis spine
score, NA Not applicable, SD Standard deviation, SEM Standard error of
the mean.
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blast activity and bone growth, bone–specific alkaline
phosphatase (BALP) [9] in patients with spondyloarthritis
who were treated with a TNF inhibitor [10].
It has been established that bone remodeling mole-
cules, particularly Dkk-1 and sclerostin down-regulating
bone formation, do not correlate, in AS patients, with
CRP levels [11,12]. It is not known whether the disease
activity as assessed with BASDAI, a clinical tool measu-
ring disease activity based on information from the pa-
tient, is related to measured levels of markers of bone
remodeling and degree of structural damage.
Therefore the present study aimed at testing bone remod-
eling and inflammatory markers in AS patients with high
and low disease activity to check whether the disease activity
measured by BASDAI influence the expression of bone re-
modeling molecules and degree of structural damage.
Methods
The study population comprised 78 consecutive AS pa-
tients screened for eligibility to anti-TNF therapy and 23
healthy individuals. Patients were diagnosed with AS
according to the modified New York criteria and were
TNF inhibitor and synthetic disease modifying anti-
rheumatic drugs (DMARDs) naïve. There were 50 AS
patients with high disease activity and 28 with low dis-
ease activity. Patients were considered as having high
disease activity if Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) was ≥4, patient’s back pain vis-
ual analogue scale (VAS) ≥4 cm, patient’s global activity
of disease was >5 cm and if they were refractory to at
least two NSAIDs. All patients were using NSAIDs, on
regular basis or on demand. The patients had predomi-
nantly axial disease with 21.8% having additional peri-
pheral signs; 96.1% were HLA-B27 positive.
Serum samples for assessment of bone remodeling
markers and markers of inflammation were obtained in
all patients and controls. Samples were stored at – 80
< degrees > C. Serum level of Dkk-1, sclerostin, Wnt-3a,
BMP-7, OPG, MMP-3, BALP, and CRP, TNF, IL-6 and
IL-18 were measured by commercially available enzyme
linked immunosorbent assay (ELISA) test (Dkk-1, BMP-7,
MMP-3, BALP, R&D System Inc, Minneapolis, MN, USA;
sclerostin, Wnt-3a, EIAab Science Co. Ltd., Wuhan, China;
OPG, Biomedica, Wien, Austria). BASDAI was calculated
in all patients. Forty six patients underwent x-ray study of
cervical and lumbar spine to determine modified Stoke’s
ankylosing spondylitis spine score (mSASSS) values. The
Study was approved by the Jagiellonian University Bio-
ethics Committee. All patients gave written informed
consent to participate.
The database management and analyses were performed
with SAS 9.2 (SAS Institute Inc., Cary, NC, USA). Means
were compared either with Student’s t test or, in case ofnon-normal distributions, with Wilcoxon test as supplied
in the proc npar1way procedure. The proportions were
compared with the chi-square test, and the associations
with the correlation analysis as implemented in the proc
corr precedure of the SAS system. All P values are two-
sided, and the 5% level of significance has been adopted
throughout.
Results
The mean (SD) age of 50 patients with high disease ac-
tivity (84.62% men) was 37.8 (11.6) years, and was sig-
nificantly higher than in low disease activity and control
groups (Table 1). The average duration of the disease
(SD) in patients with high activity was 9.0 (6.7) years
and did not significantly differ from low activity group
with 7.2 (5.0) years. In high activity group the median
CRP (SEM) was 23.4 mg/l (3.87) and median clinical
activity of the disease as assessed by BASDAI (SEM)
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low activity group (Table 1).
The mean serum levels (SEM) of the seven studied
markers of bone remodeling and four markers of inflam-
mation in three studied groups are given in Table 1.
Briefly, sclerostin serum level was significantly higher
in AS patients with high disease activity in comparison
to healthy subjects. Wnt-3a and Dkk-1 level were sig-
nificantly lower in high activity group compared to
low activity group and healthy controls. There were no
significant correlations between remodeling molecules,
inflammatory markers, BASDAI and mSASSS (including
lack of correlation between CRP and sclerostin) except
negative correlation between sclerostin and Dkk-1 in
high disease activity group (R = −0.28, P = 0.048).
Levels of CRP, TNF and IL-6 were significantly higher
in each AS group than in controls, but were not differ-
ent between AS groups, except CRP which was higher in
active group.
To assess the interaction between disease activity and
structural damage in AS patients, we checked the mean
mSASSS values in groups with high (BASDAI ≥ 4) and
low (BASDAI < 4) clinical activity. The median mSASSS
values were not significantly different between groups
(Table 1).
Discussion
In this cross-sectional study we showed that serum level
of sclerostin was significantly higher in AS patients with
high disease activity than in healthy subjects. Although
numerically greater, the difference between level of
sclerostin in the high activity group and the low activity
group did not reach statistical significance (0.34 vs.
0.21 ng/ml, P = 0.09, high vs. low AS activity, respect-
ively). The sclerostin level in the group with low disease
activity was not different from the control subjects.
Higher level of sclerostin in active AS group agreed with
higher inflammation activity as expressed by significantly
greater CRP level in these patients in comparison to low
activity group and healthy controls. However, no correl-
ation between sclerostin and CRP was found, suggesting
that sclerostin may not be directly linked to acute phase
response. Likewise level of Dkk-1 was not correlated with
CRP in our study, which is concordant with other pub-
lished data [11,12]. This confirms that interaction be-
tween inflammatory markers and inhibitors of bone
formation in AS is complex and might not translate into
simple correlations.
To check whether a novel, more objective measures of
disease activity would have more bearing on the results,
we retrospectively substituted BASDAI with the Ankylo-
sing Spondylitis Disease Activity Score incorporating the
CRP level (ASDAS-CRP) [13]. We found no correlation
between ASDAS-CRP and sclerostin level. Moreover, wefound no difference in sclerostin levels when ASDAS-
CRP 3.5 cut-off was used instead of BASDAI 4.0 cut-off.
We also compared the mSASSS scores in these groups
and we found no statistically significant difference be-
tween median values of mSASSS (P = 0.13), a finding re-
producing our main results where BASDAI was used as
clinical measure of AS activity.
In contrast to our results, Appel et al. reported serum
level of sclerostin to be significantly lower in 46 AS pa-
tients with mean disease duration (SD) of 5.3 years (2.6)
in comparison to healthy controls [14]. In a subgroup
analysis level of sclerostin over 2-year follow-up was sig-
nificantly higher in patients with no syndesmophyte de-
velopment than in patients with new syndesmophyte
growth. However, the authors of that report did not
mention the BASDAI and CRP values in the studied
groups which precludes direct comparison with our high
activity AS group. Furthermore, patients were selected
from a database on the grounds that their blood samples
and x-ray data were available for 2 years in yearly inter-
vals (0, 1 and 2 year) to capture least significant change
in syndesmophyte growth, which may have introduced a
bias. Therefore we assume that majority of their pa-
tients, having lower level of sclerostin than healthy con-
trols, probably had low disease activity and would have
had possibly higher mSASSS values, which were not
reported again. They conclude that low sclerostin level
in AS was found to be associated with syndesmophyte
formation and may be useful as a biomarker to assess
the risk of developing syndesmophytes in AS [14]. This
contrasts our results where higher sclerostin level in
high disease activity group was not associated with lower
level of syndesmophyte formation since mSASSS in our
both groups was comparable.
To our best knowledge, only one study addressed the
issue of BASDAI influence on sclerostin and Dkk-1
serum level in AS patients [12]. In the AS groups with
BASDAI ≥ 4 and BASDAI < 4, the authors reported no
differences of Dkk-1 and sclerostin levels in the
former contrary, the latter concordant with our re-
sults. In addition they found no differences between
all AS patients and healthy controls with regard to
sclerostin and Dkk-1 serum concentration. However
23 out of 55 patients studied were already receiving
TNF inhibitor treatment, for a median of 24 (16–33)
months, which may have influenced the results, in
particular CRP and BASDAI. In addition, the radio-
graphic data were not reported, making direct com-
parisons with our data difficult.
It has been shown in an animal model of chronic
inflammatory arthritis that TNF induces skeletal ex-
pression of Dkk-1 which in turn triggers sclerostin pro-
duction [3], both molecules being potent inhibitors of
new bone formation. Interestingly, in our study both
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cally different across the high and low AS activity
group. This might suggest that there are other molecu-
lar mechanisms, than related to acute-phase response,
responsible for modulation of Dkk-1 and sclerostin
serum level in AS patients with high disease activity.
Moreover, it may be hypothesized that there are high
and low producers of sclerostin among AS patients
which requires independent confirmation. In addition,
our negative correlation between sclerostin and Dkk-1
in high disease activity group (R = −0.28, P = 0.048) is
against the Heiland et al. conclusion that neutralization
of Dkk-1 resulted in decreased expression of sclerostin
in osteocytes [3]. The possible explanation of the differ-
ence between our data and those reported by Heiland
et al. rests with the fact that we used serum and not
bone tissue samples.
Wnt-3a level was significantly lower in our AS group
with high disease activity compared to AS group with
low disease activity and healthy controls and this is in
line with formerly reported inhibitory effect of sclerostin
on Wnt-3a [3]. In low disease activity group we found
increased Dkk-1 serum level which may be a counter-
balancing mechanism attenuating the Wnt signaling,
active in AS with low activity of inflammation. This hy-
pothesis was suggested by Daoussiss et al. who found
increased level of Dkk-1 after 12 weeks of anti-TNF
treatment in 8 patients with AS resulting in signifi-
cantly decreased CRP level [15]. Indeed, in our data,
Wnt-3a and Dkk-1 levels in low AS activity group with
low CRP level were the highest and significantly greater
than in high activity group and healthy controls. How-
ever, it needs to be mentioned that our low-CRP/low
AS activity group cannot be directly compared with the
findings in the post anti-TNF treatment patients
reported by Daoussiss et al.
Our results must be viewed in the context of their
limitations. The sample size was moderate, although in
line with other research in this field reported in litera-
ture. In our study we chose Wnt-3a from among other
Wnt molecules. However, the results obtained for this
particular protein cannot be viewed as representative
for the rest of the Wnt family. Such selection was based
on search of the available literature and on its key role in
direct bone formation, most likely due to activation of
canonical Wnt signaling pathway [16,17]. The remaining
issue is whether serum level of sclerostin is stable to war-
rant the conclusion that its elevated level influences
mSASSS, the latter reflecting rather longstanding process
of bone remodeling. Although we do not have longitu-
dinal data, the study by Appel et al. provide evidence that
sclerostin serum level was continuously raised for two
years in a group with no radiographic progression of
syndesmophytes [14].Conclusions
In conclusion, serum level of sclerostin was elevated in
high disease activity AS group and was associated with
decreased serum level of Wnt-3a. Median structural
damage measured by mSASSS in both groups was com-
parable. This suggests that sclerostin might be respon-
sible for suppression of molecules inducing new bone
formation in AS. It also indicates that higher clinical ac-
tivity in AS might not be per se associated with greater
new bone formation.
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